SU2C Scientific Research Teams
Emile E. Voest, M.D., Ph.D.Scientific Research Team:
Emile E. Voest, M.D., Ph.D.
Emile E. Voest, M.D., Ph.D., is head of the department of medical oncology at the University Medical Center Utrecht. He also serves as chair of the Center for Personalized Cancer Treatment (a joint effort of the UMC Utrecht, Erasmus MC and NKI/AvL), director of the Graduate School of Life Sciences Ph.D. program “Clinical and Translational Oncology” of the University of Utrecht and as chair of the scientific council of the Dutch Cancer Society.
His translational research has focused on improving systemic treatment for patients with cancer. This includes the clinical development of targeted agents, discovery and validation of biomarkers and identification of new targets of treatment to overcome chemoresistance.
Voest became registered as a medical doctor in 1985. He became board certified as an internist in July 1993, and as a medical oncologist in January 1995. He completed his Ph.D. program on the enhancement of the efficacy of anthracyclines by modulation of iron metabolism in tumor cells in June 1993 (cum laude). In 1994 and 1995, he was a postdoctoral fellow of the Dutch Cancer Society. As a postdoctoral fellow he joined the laboratory of Dr. Judah Folkman at Children’s Hospital, Harvard Medical School in Boston, Mass., and worked on endogenous inhibitors of angiogenesis. Thereafter, he worked at the Netherlands Cancer Institute in Amsterdam on high dose chemotherapy. In November 1999, he became a full professor in medical oncology. He currently serves in a variety of scientific committees and advisory boards. He has several patents to his name in the field of angiogenesis and biomarkers and recently founded the spin-out company PIFA Therapeutics that investigates reversal of resistance to anti-cancer treatment. He has co-authored more than 180 manuscripts that together have been cited almost 6,000 times.
The department of medical oncology at the UMC Utrecht has several preclinical and translational research lines including mitotic checkpoints, chemoresistance and genetic analyses of tumors in relation to treatment outcome. The program also includes a large phase I unit with a devoted team of nurses, scientists, data managers and clinicians. The preclinical research program and the early clinical trial program are mutually supportive and have a strong interaction.
Voest will serve as one of the team leaders in the Stand Up To Cancer International Translational Research Grant “Prospective Use of DNA-guided Personalized Cancer Treatment.”